Loading
No description yet: the sentence for this tag has not been written. 13 records carry it: 8 drugs, 4 people, 1 roadmap.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
AccuScan AccuScan A whole-genome blood test for leftover cancer from AccuraGen that corrects sequencing errors read by read, so it can add up thousands of a tumour's mutations. | Emerging | Colorectal cancer, Oesophageal cancer, Melanoma | none | test | |
brPROPHET brPROPHET Burning Rock's personalised blood test for leftover lung cancer after surgery, which tracks up to 50 of the tumour's own mutations. | Emerging | Non-small-cell lung cancer | none | test | |
C. Ola Landgren Chief of Myeloma and Director of the Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami · Sylvester Comprehensive Cancer Center, University of Miami Showed that MGUS precedes essentially all myeloma and leads MRD-driven trials aiming for cure without transplant. | Multiple myeloma | none | myeloma, precursor | ||
CancerDetect CancerDetect IMBdx's personalised blood test for leftover cancer, from Seoul, which adds a set of common treatable mutations to the patient's own. | Emerging | none | none | test | |
ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment Blood carries fragments of tumour DNA. This roadmap follows the tests that read them, from the first sighting in 1948 to blood tests that now choose a drug, spare chemotherapy, or screen for many cancers at once, and it lists the readouts to watch next. | Triple-negative breast cancer, Gallbladder cancer | none | ctdna, liquid-biopsy, mced | ||
Enspyre Enspyre An experimental blood test from Biofidelity in Cambridge that enriches the tumour's mutated DNA before sequencing, so it needs far less sequencing to find leftover cancer. | Emerging | Non-small-cell lung cancer | none | test | |
Foresight CLARITY Foresight CLARITY A blood test for leftover lymphoma that looks for several of the tumour's mutations sitting on the same piece of DNA, which lets it see far smaller traces than tests that look for one mutation at a time. | Emerging | Diffuse large B-cell lymphoma | none | test | |
Geneplus personalised MRD assay Geneplus-Beijing's personalised blood test for leftover cancer in bowel, breast and lung cancer, which labels each tracked mutation as present in all tumour cells or only some. | Emerging | Colorectal cancer, Breast cancer, Non-small-cell lung cancer | none | test | |
MinerVa Prime MinerVa Prime Genecast's personalised blood test for leftover cancer, used to follow patients with EGFR-mutated lung cancer after surgery in the EVIDENCE trial. | Emerging | Non-small-cell lung cancer | none | test | |
Nicola Gökbuget Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt · University Cancer Center Frankfurt (UCT) Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL. | Acute lymphoblastic leukaemia | none | all, cooperative-group | ||
OriMIRACLE S OriMIRACLE S OrigiMed's personalised blood test for leftover cancer, which deliberately tracks only mutations shared by every tumour cell. | Emerging | Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Osteosarcoma | none | test | |
Peter Hillmen Emeritus Professor of Experimental Haematology, University of Leeds · Leeds Cancer Centre, St James's University Hospital Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL. | Chronic lymphocytic leukaemia | none | cll, uk | ||
Viktor A. Adalsteinsson Director, Gerstner Center for Cancer Diagnostics, Broad Institute of MIT and Harvard · Broad Institute of MIT and Harvard Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests. | none | none | ctdna, diagnostics |